…I wouldn't be shocked if Roche tries adding a third drug with a new mechanism in the not too distant future (I believe they have their own internal Helicase program). It seems now there are a number of qD candidates in the <200-300mg range so co-formulation may be a bit more practical.
I agree, and I would add that a purine nuke such as IDX184 can be considered a different MoA from RG7128, which is a pyrimidine nuke. Note that PSI-7977 is also a pyrimidine nuke, so we can presumably rule out a cocktail that contains both RG7128 and PSI-7977.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.